Capricor Therapeutics has initiated legal action against its distribution partners to ensure that patients with Duchenne muscular dystrophy (DMD) can access a potentially life-changing cell therapy. The lawsuit centers on …
Tag:
Drug Development
-
-
FDA Awards National Priority Vouchers to Psychedelic Drug Developers On April 24, 2026, the U.S. Food and Drug Administration (FDA) announced the issuance of three national priority vouchers to companies …
-
The Interplay Between Patent Rights and Competition Patent rights and competition are intrinsically linked, forming a complex relationship that impacts market dynamics and innovation. While patents incentivize innovation by granting …
-
FDA Faces Critical Juncture in Approving New Gene Therapies, Warns Former Commissioner Hundreds of individualized treatments for rare diseases could become available over the next decade, but their path to …
-
Trump and Epstein Files: DOJ Releases Additional Documents Amidst Allegations The Justice Department recently released additional documents from the Jeffrey Epstein files, containing decades-ancient sexual assault allegations against President Donald …
-
Biotech Scorecard: Aldeyra Therapeutics, Sarepta and the Changing Landscape of Biotech Commerce The biotech sector is navigating a period of shifting dynamics, marked by scrutiny of corporate actions, leadership transitions, …
-
Biotech VC Aids Epstein Associate’s Return to Industry A biotech investor with ties to convicted sex offender Jeffrey Epstein is making a comeback in the venture capital world, aided by …
-
Biotech Investor Boris Nikolic Makes Comeback Despite Epstein Ties Boris Nikolic, a venture capitalist and former science advisor to Bill Gates, is re-emerging in the biotech investment world despite past …
-
Corporate Medicine Bans Face Legal Test in Oregon A legal battle in Oregon is challenging the state’s recently revised ban on corporate medicine, according to reporting by STAT News. The …
-
FDA Vaccine Chief Dr. Vinay Prasad Departs Agency Amid Controversy Dr. Vinay Prasad, the director of the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration, …
Newer Posts